In combination with the gating potentiator VX-770, VX-809 achieved only modest benefit in CF patients homozygous for the ΔF508 mutation [20], which might be attributed in part to the destabilization of ΔF508-CFTR upon chronic exposure to VX-770 [21,22]. Here, CFTR is linked to cystic fibrosis.